SAN DIEGO, Oct. 23 Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference in SanDiego on Tuesday, October 28, 2008 at 10:30 a.m. PT. Mark G. Foletta, Amylin'sSenior Vice President of Finance and Chief Financial Officer, will beproviding a corporate overview.
The live presentation will be Web cast, and a recording will be madeavailable following the event. The Web cast and recording will be accessiblethrough Amylin's corporate Web site, located at http://www.amylin.com. Toaccess the live Web cast, please log on to Amylin's site approximately fifteenminutes prior to the presentation to register and download any necessary audiosoftware.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed toimproving lives through the discovery, development and commercialization ofinnovative medicines. Amylin has developed and gained approval for twofirst-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)injection and BYETTA(R) (exenatide) injection. Amylin's research anddevelopment activities leverage the company's expertise in metabolism todevelop potential therapies to treat diabetes and obesity. Amylin isheadquartered in San Diego, California with over 2,000 employees nationwide.Further information on Amylin Pharmaceuticals is available athttp://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.